Episurf Medical is planning the 300th surgery with its Episealer® personalized implant, to occur in coming weeks. This represents a doubling of the number of procedures performed as of mid-4Q16.
Episealer devices treat localized cartilage damage in the knee. The implants and surgical tools are approved under the CE Mark; in 2Q17, the company indicated that it was engaged in obtaining FDA’s views about classification and the regulatory requirements that may be applicable to the Episealer device.
Episurf Medical is planning the 300th surgery with its Episealer® personalized implant, to occur in coming weeks. This represents a doubling of the number of procedures performed as of mid-4Q16.
Episealer devices treat localized cartilage damage in the knee. The implants and surgical tools are approved under the CE Mark; in 2Q17, the...
Episurf Medical is planning the 300th surgery with its Episealer® personalized implant, to occur in coming weeks. This represents a doubling of the number of procedures performed as of mid-4Q16.
Episealer devices treat localized cartilage damage in the knee. The implants and surgical tools are approved under the CE Mark; in 2Q17, the company indicated that it was engaged in obtaining FDA’s views about classification and the regulatory requirements that may be applicable to the Episealer device.
Copy to clipboard 
